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ABSTRACT
The prevalence of type 2 diabetes continues to rise nationally and internationally,
impacting millions of people worldwide. Type 2 diabetes results from insulin resistance leading
to chronic hyperinsulinemia and dysfunction of the insulin producing β cells of the pancreas.
While environmental factors can influence the development of type 2 diabetes, research has
shown genetics are also involved. Gli-similar 3 (Glis3), a Krüppel-like zinc finger transcription
factor, has been identified as a novel regulator of insulin transcription. Evidence has shown that
loss-of-function Glis3 mutations decrease insulin expression, implicating Glis3 in the
development of type 2 diabetes. However, the distinct role Glis3 plays in the development of
type 2 diabetes remains unclear. To better understand the role of Glis3 in pancreatic β cells, we
utilized the CRISPR/Cas9 system to target Glis3 for cleavage, knocking down Glis3 in the rat β
cell line, INS1 832/13. Decreased Glis3 expression in rat β cells maintained under chronically
elevated glucose conditions exacerbated β cell dysfunction, supporting the hypothesis that
decreased Glis3 expression promotes the development of diabetes. We then applied
the CRISPR/Cas9 system to knockout Glis3 in zebrafish to better understand its role in
pancreatic development, β cell dysfunction, and the development of type 2 diabetes in vivo. The
CRISPR/Cas9 knockout has been designed and microinjected into zebrafish, and we are
currently completing the genotyping process. Taken together, the in vitro and in vivo CRISPR
findings will better characterize the role of Glis3 in insulin regulation, β cell dysfunction, and the
development of type 2 diabetes.
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INTRODUCTION
Type 2 diabetes is a chronic condition characterized by the body’s inability to regulate
blood glucose using insulin, ultimately resulting in chronic hyperglycemia, insulin resistance,
and altered metabolic processes (Wu et. al. 2014). The prevalence of type 2 diabetes continues to
grow worldwide, impacting the lives of more than 425 million people worldwide, including over
30 million people in the United States. (Rachdaoui 2020). Many risk factors can lead to type 2
diabetes, some of the most well-known being obesity, sedentary lifestyle, and unhealthy diet
(Laakso 2019). Recent research identifying approximately 88 genetic loci involved in the
development of type 2 diabetes implicates genetic factors which act in combination with the
environmental and lifestyle factors previously identified (Brown and Walker 2016).
Blood glucose homeostasis is closely regulated by the production of insulin, a pancreatic
hormone that is released in response to rising blood glucose levels (Kahn et. al. 2014). In healthy
individuals, an increase in blood insulin levels follows the ingestion and metabolism of glucose.
High blood glucose triggers the release of insulin from pancreatic β cells, initiating the cellular
uptake of glucose through binding to insulin receptors on muscles and other peripheral
tissues. Insulin binding to its receptors promotes the vesicular fusion of the glucose transporter
type 4 (GLUT4) with the plasma membrane and allows the movement of glucose out of the
bloodstream and into nearby tissues (Haeusler et. al. 2018). As a result, blood glucose levels
return to normal and the glucose can be utilized in tissues to perform energy-requiring functions.
People with type 2 diabetes often experience insulin resistance prior to the onset of
disease. Under these conditions, insulin is produced normally, but the hormone has a reduced
efficacy in stimulating the activation of the GLUT4 receptor. In the early stages, referred to as
“pre-diabetes,” β cells release increased amounts of insulin (hyperinsulinemia) to attempt to
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compensate for this reduced insulin function and encourage tissues to take in the extra blood
glucose (Rachdaoui 2020). Over time, hyperinsulinemia and increasing insulin resistance leads
to β cell dysfunction, which is characterized by decreased β cell number and function as β
cells undergo exhaustion and apoptosis due to continually increased insulin production
(Christensen and Gannon 2019). The inability for β cells to compensate for chronically elevated
blood glucose levels and the perpetuation of insulin resistance ultimately lead to the development
of type 2 diabetes (Kahn et. al. 2014).
The genetic factors implicated in type 2 diabetes range from those involved in β cell
development to insulin resistance (Kahn et. al. 2014). One gene, Gli-Similar 3, was identified as
an important regulatory factor of insulin. Glis3 is a gene that codes for a Krüppel-like zinc-finger
transcriptional regulator that has been implicated in the development of polycystic kidney
disease and diabetes (Lichti-Kaiser et. al. 2012). Using in situ hybridization and northern blot
analysis, Glis3 expression was found in the kidney, uterus, brain, thymus, pancreas, skeletal
muscle, lungs, liver, and ovaries of mouse embryos (Kim et. al. 2003). Additionally, humans
with frameshift mutations that resulted in the loss of the Glis3 C-terminus were found to have a
condition characterized by neonatal diabetes, polycystic kidneys, and congenital hypothyroidism
(Senée et. al. 2006).
In later studies, Glis3 knockout mice were generated and displayed a phenotype similar to
that of the human altered-Glis3 condition, having developed both neonatal diabetes and
polycystic kidneys (Kang et. al. 2009). Reduced β cell number and functioning was also seen in
Glis3 knockout mice, suggesting that Glis3 may be vital to the development and functional
regulation of β cell specification and maturation in the pancreas (Kang et. al. 2009). Additional
evidence supporting the role of Glis3 involvement in the development of type 2 diabetes was
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found through genome-wide association studies (GWAS), which have associated Glis3
mutations with impaired glucose regulation, β cell function, type 1, and type 2 diabetes (Barrett
et. al. 2009; Dupuis et. al. 2010). Further, Glis3 was found to physically interact with multiple
transcription factors—pancreatic duodenal homeobox 1 (Pdx1), v-maf masculoaponeurotic
fibrosarcoma oncogene homolog a (MafA), and neuronal differentiation 1 (NeuroD1)—involved
in the expression of insulin (Lichti-Kaiser et. al. 2012). Loss of Glis3 expression dramatically
decreased binding of Pdx1, MafA, and NeuroD1 to the insulin promoter and subsequently
decreased insulin transcription, suggesting that Glis3 may be required as a pioneer factor to alter
the chromatin state of the insulin promoter prior to activation by the core machinery (ZeRuth et.
al. 2013).
Despite being characterized as an insulin gene regulator and implicated in the development
of type 2 diabetes, the mechanisms through which Glis3 acts are not well understood. The goal
of this research is to better understand the role of Glis3 in β cell dysfunction, type 2 diabetes, and
development of the pancreas. To further explore the action of Glis3, CRISPR-Cas9 was utilized.
Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein
(Cas9) is a method of gene editing that uses guide-RNA (gRNA) to target a specific portion of a
gene that Cas9, a nuclease that targets DNA to induce a double stranded break, will cleave. The
cell’s machinery will then repair the cut portion of DNA using non-homologous end joining
(NHEJ) or homology directed repair (HDR) (Savic and Schwank 2016). The cell will rely on
NHEJ when a homologous chromosome is not nearby, like in the G1 phase of the cell cycle,
resulting in insertions or deletions that are likely to induce a frameshift mutation. In the presence
of a homologous section of DNA, HDR will be induced, using the homologous chromosome as a
template to repair the lesion with high fidelity (Ma et. al. 2014). CRISPR was first discovered as
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a bacterial immune response to invading viral DNA, but it has since been developed as a
biomedical tool for genome editing. CRISPR has been used to research the underlying
mechanisms of diseases, create disease animal models, and confirm disease targets with the
eventual goal of treating human diseases (Lino et. al. 2018).
To better understand the mechanism by which Glis3 acts in pancreatic development, β cell
dysfunction, and type 2 diabetes, a CRISPR knockdown was generated in rat β cells. This
knockdown deleted a portion of the Glis3 gene in Exon 3, inducing a frameshift mutation. The
CRISPR’ed cell line was then used to examine the impact of Glis3 knockdown on insulin
regulation at the cellular level. The knockdown showed that without Glis3, insulin was
downregulated, indicating that the knockdown worked. An additional gRNA was generated to
target and cleave a portion of Glis3 Exon 4 in zebrafish. The Glis3 knockout was tested in
zebrafish to examine the effect of nonfunctional Glis3 on the development of the pancreas. The
Glis3 knockout is currently being genotyped using Sanger sequencing. Combined, these results
better characterize the mechanisms through which Glis3 acts during the development of the
pancreas and type 2 diabetes.
METHODS
Cloning of DR274 sgRNA constructs
Prior to cloning, pDR274 was digested using BsaI and then dephosphorylated using
alkaline phosphatase. Templates for gRNA targeting exon 4 of glis3 were designed using a
gRNA design tool (Integrated DNA Technologies) and sequences were selected that had the
highest predicted cutting efficiency with the lowest predicted off-target effects. Double stranded
oligonucleotides containing the template for the selected gRNA were synthesized with BsaI
overhangs for cloning into digested pDR274. These sgRNA constructs were phosphorylated and
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cloned into pDR274 downstream of a T7 promoter and the tracrRNA sequence giving rise to
pDR274-glis3EX4-2 and pDR274-glis3EX4-4.
In vitro transcription of sgRNA and subsequent purification and gel analysis
pDR274-glis3EX4-2 and pDR274-glis3EX4-4 were linearized with HindII and purified
by phenol:chloroform extraction followed by ethanol precipitation. sgRNA was generated by in
vitro transcription using the MEGAshortscript T7 transcription kit (Ambion) following the
manufacturer’s protocol. DNase was added to digest template DNA. The RNA was purified
using lithium chloride precipitation and subsequently visualized on a denaturing agarose gel to
confirm the presence of a single band of ~80 nt.
In vitro CRISPR/Cas9 digestions
To test the efficacy of the glis3 gRNA, 3 nM PCR amplified glis3 cDNA was mixed with
30 nM gRNA and 30 nM Cas9 protein (New England Biolabs) and incubated at 37° C for 15
min. Samples were subsequently incubated with proteinase K for 10 min at RT and analyzed on
an agarose gel stained with ethidium bromide.
Electroporation of sgRNA/Cas9 into INS1 832/13 cells
22.5 pmol Glis3EX3A and B sgRNA were combined with 3,750 ng Cas9 v2 protein
(ThermoFisher Scientific) and incubated at RT for 10 min to form protein-RNA complexes.
Combined CRISPR reagents were mixed with ~250,000 INS1 832/13 cells and electroporated
using the NEON electroporation system using settings 1650V/10 ms/3 pulses. Electroporated
cells were grown in 2 ml antibiotic free media and analyzed 24 h later. CRISPR efficiency was
analyzed by PCR amplifying a 500 bp Glis3 fragment from exon 3 from control and CRISPR
modified gDNA and cDNA.
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Microinjection of sgRNA/Cas9 into jh2 zebrafish zygotes
jh2 1-2 cell stage embryos were injected with ~ 1 nl of an injection solution containing
6,250 ng Cas9 v2 protein (ThermoFisher Scientific), 2,100 ng EX4-2 and EX4-4 sgRNA, and
0.05% phenol red in T10E0.1 using a PicoSpritzer III pneumatic microinjector.
Gene Expression Analysis by RT-PCR
RNA was isolated from INS1 832/13 cells using a PureLink RNA mini kit (Invitrogen)
according the manufacturer’s specifications. Equal amounts of RNA were used to generate
cDNA using a high capacity cDNA kit (Applied Biosystems), and cDNA was analyzed by
quantitative real-time PCR. All qRT-PCR was performed in triplicate using PowerUP SYBR
green master mix (Applied Biosystems) and an Applied Biosystems 7500 RT-PCR system. The
average Ct from triplicate samples was normalized against the average Ct of 18S rRNA. A
student’s two-tailed t test was used to assess the significance (indicated by p < 0.05) of the
results. Primers used for RT-PCR are listed in Table X (make 500 bp fragment).

Table X: Primers used for Exon3A-3B INS1 832/13 cell RT-PCR.
CRISPR Zebrafish Tail Clipping
Exon4-2/Exon4-4 CRISPR zebrafish were anesthetized by submerging them in a solution
of 4 mL tricaine in 100 mL fish water. They remained submerged until they stopped moving and
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their breathing slowed, about 5 minutes. The fish were then placed on a dissection tray, and a
clean razor blade was used to cut the fin away from the base of the body. After clipping the tail
and placing the fin in a 1.5 mL tube, the fish was returned to an individual tank and observed
until it began moving again. The fin samples were stored in a -20°C freezer until DNA
extraction.
Dirty DNA Extraction from Zebrafish Fin
100 mL of 50 mM NaOH was added to each sample, submerging the fin clipping. They
were heated on a 95°C heating block for 10 minutes. After heating, the samples were cooled to
4°C in a refrigerator. 10 μL (1/10 volume) of 1 M Tris HCl pH 8 was added to each sample, and
the samples were centrifuged at maximum speed for 3 minutes. The supernatant was collected
from each sample and transferred to a clean tube before undergoing PCR amplification.
PCR Amplification and Genotyping of CRISPR DNA
DNA extracted from each CRISPR zebrafish was amplified using PCR. 1 μL DNA from
each sample was combined with primers and GreenTaq Master Mix. The primers used for this
PCR amplification are listed in Table Y. An initial denaturation was run for 2 minutes at 95°C.
Then, the samples undergo 35 cycles of denaturation (30 seconds at 95°C), annealing (30
seconds at 55°C), and elongation (1 minute at 72°C). After the repeated cycles, the samples run
through a final elongation for 7 minutes at 72°C. The PCR products were then visualized on an
agarose gel and Sanger sequenced.

Table Y: Primers used for PCR amplification of Exon4-2/4-4 DNA.
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RESULTS
Production of CRISPR/Cas9 Reagents for In Vitro Studies
Previous studies have indicated that Glis3 plays a role in insulin regulation, however the
precise roles of the transcription factor within the mature β cells have been unexplored. To
characterize the function of Glis3 in β cells, a Glis3 knockdown was generated in the rat β cell
line, INS1 832/13. CRISPR/Cas9 was used to create a frameshift mutation in Glis3 Exon 3,
which precedes the DNA binding and transactivation domains to render Glis3 non-functional. To
produce sgRNA, we cloned the gRNA template (Exon3A and Exon3B) into pDR274
downstream of a T7 promoter and the tracrRNA sequence and linearized the construct using DraI
immediately downstream of the inserted template DNA (Figure 1a, Figure 1b). The linearized
product was then used for in vitro transcription to generate the sgRNA. Visualization on an
agarose gel showed the Exon3A sgRNA was the proper size (177 nucleotides) (Figure 1c).

A
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Figure 1: a) Exon3B and Exon3A gRNA were designed to target Exon 3 in rat Glis3. Cas9 will
be recruited by each gRNA and cleave two base pairs before the Exon3B PAM site and two base
pairs following the Exon3A PAM site. This cleavage will result in the removal of 55 base pairs
from Exon 3, causing a frameshift mutation and resulting in non-functional rat Glis3. b) DraI
digestion was used to linearize the DR274 vector (2.1 kb). c) In vitro transcription showed
successful production of Exon3A sgRNA.
CRISPR/Cas9 Cleaves Glis3 In Vitro
The efficacy of the Exon3A sgRNA was tested in vitro with Cas9 to ensure proper
cleavage of Glis3. To accomplish this, Glis3 cDNA (2.7 kb) was PCR amplified and digested
using Cas9 in the presence or absence of Exon3A sgRNA. Cas9-directed cleavage was expected
to generate a 2.2 kb and a 0.5 kb fragment. When visualized on an agarose gel, the sgRNA
targeted Glis3 with > 90% efficiency (Figure 2). Digestion with Cas9 minus the sgRNA served
as a negative control while digestion of the fragment with XhoI served as a positive control.
Without the Exon3A sgRNA, Cas9 did not successfully target and cleave Glis3, indicating that
the sgRNA was necessary for proper targeting of Glis3. Successful digestion of Glis3 by XhoI
also ensured that the Glis3 amplification could be targeted and digested properly.
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Figure 2: Rat Glis3 was PCR amplified and tested
under three conditions: Cas9 digestion, Cas9
digestion with Exon3A sgRNA presence, and XhoI
digestion (positive control). The decrease in the size
of Glis3 digested with Cas9 in the presence of
Exon3A sgRNA indicates that Exon3A sgRNA
successfully targets Glis3 for Cas9 cleavage. The
intact Glis3 amplicon was 2.7 kb. Cas9-mediated
cleavage was expected to generate a 2.2 kb and a
0.5 kb fragment. XhoI digestion produces 1.7 kb
and 1.1 kb fragments.
Optimizing Exon3A sgRNA for Glis3 Targeting in Rat β Cells
To assess CRISPR efficiency in a β cell line, we electroporated Exon3A sgRNA and
Cas9 protein into rat INS1 832/13 cells. The procedure was first optimized by electroporating
Exon3A sgRNA at two concentrations—400 ng and 600 ng—and Cas9 at a 3:1 ratio into INS1
832/13 cells. 24 hours after electroporation, genomic DNA was extracted from the cells and
cleavage was assessed using a T7 endonuclease based genomic cleavage assay (Figure 3). The
extracted Glis3 showed in the expected 67 base pair and 429 base pair fragments under both the
400 ng and 600 ng Exon3A conditions, but the 600 ng-condition was more efficient. This was
compared to a positive control (Human AAVS1 locus) and genomic DNA collected from
untransfected cells. The proper cleavage of the positive control and absence of cleavage in the
DNA that was not transfected ensures the targeting and cleavage of Glis3 by CRISPR/Cas9.
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Figure 3: Genomic DNA extracted from the
CRISPR-electroporated cells was treated with a
detection enzyme and incubated at 37°C for 1 hour.
The formation of 429 base pair fragments in the
cells treated with Exon3A sgRNA indicate that the
sgRNA properly targeted the DNA for Cas9
cleavage. Treatment of cells with 600 ng of Exon3A
sgRNA was optimal for Cas9 targeting.

Analyzing Exon 3 Knockdown in Rat β Cells
To produce a β cell knockdown cell line, INS1 832/13 cells were electroporated with
Exon3A and Exon3B gRNA simultaneously using the optimized conditions. Exon3A and
Exon3B sgRNA were designed to cut at two different loci within Exon 3 in Glis3, resulting in
the excision of 55 base pairs by Cas9 in Exon 3 (Figure 1a). Using this strategy, genotyping can
be performed by simple agarose gel electrophoresis without relying on sequencing. After the
electroporation into cells, a 400 base pair fragment from Glis3 Exon 3 was PCR-amplified from
INS1 gDNA and visualized on an agarose gel (Figure 4a and 4b). Compared to untreated cells,
the electroporated cells showed cleavage of 55 base pairs at > 90% efficacy similar to what was
observed in vitro. This result was confirmed using INS1 Glis3 and INS1 Exon3A-3B Glis3
cDNA, which also exhibited a 55 base pair size difference.
To further understand the impact of the Glis3 knockdown on insulin regulation, RT-PCR
was used to measure how the levels of key insulin regulatory factors differed between INS1
11

832/13 cells and Exon 3A-3B INS1 832/13 cells under varying glucose conditions. 25 mM
glucose concentration mimicked blood glucose conditions cells would experience prior to and
after the onset of type 2 diabetes. Ins1 and Ins2 levels were measured to examine the effect of the
Glis3 knockdown on insulin presence. As expected, the Glis3 knockdown resulted in a
statistically significant decrease in Ins2 expression. Loss of Glis3 had a minimal effect on Ins1
expression (Fig 4c). Previous reports have also indicated that Glis3 has a greater effect on Ins2
transcription and may not be involved in Ins1 transcriptional regulation (ZeRuth et. al. 2013).
Glis3 overexpression experiments have identified HNF4 and HNF6 as well as MafA as possible
targets of Glis3 while Pdx1 was measured as a general marker of beta cells. However, the Glis3
knockdown did not significantly impact the expression of the other insulin transcriptional
regulators.

A

B

12

C

*
*

*

Figure 4: a) To ensure Exon 3A and Exon 3B sgRNA properly targets Glis3 Exon 3 for
cleavage, 400 base pairs of Glis3 were PCR amplified from the cells electroporated with
CRISPR constructs. Genomic DNA amplification showed cleavage of 55 base pairs with an
efficacy of > 90%. b) Proper CRISPR targeting can also be seen in cDNA PCR amplification of
Glis3 Exon 3 treated with Exon 3A and Exon 3B sgRNA. The cDNA showed cleavage of 55
base pairs by Cas9. c) RT-PCR was used to test the effect of the Exon 3A-3B knockdown on
insulin regulation by measuring expression of insulin and related regulatory factors under
varying levels of glucose. Each bar represents relative mRNA ± the standard deviation. *:
statistical significance from control cells (p < 0.05). Downregulation of Glis3 significantly*
downregulated Ins2 under 25 mM glucose conditions.
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Production of CRISPR/Cas9 Reagents for In Vivo Studies
After using CRISPR/Cas9 to successfully knock down Glis3 in rat β cells, we generated
Glis3 knockouts in zebrafish to better explore the role of Glis3 in organismal insulin regulation.
To generate this knockout, we used CRISPR/Cas9 to induce a double-stranded break in Glis3
Exon 4, which could result in a frameshift mutation upon repair. The knockout was made by
designing sgRNA (Exon 4-2 and Exon 4-4) to target Glis3 (Figure 5a). With these targets,
CRISPR/Cas9 should remove three base pairs from Glis3. Again, the Exon 4-2 and Exon 4-4
gRNA templates were cloned into a DR274 vector and linearized with DraI (Figure 5b). The
sgRNA was then generated through in vitro transcription and analyzed on an agarose gel. The gel
showed sgRNA of the appropriate size (177 base pairs), ensuring that the in vitro transcription
was successful in Exon 4-2 (Figure 5c).

A
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Figure 5: a) Figure 5a: Exon 4-4 and Exon 4-2 guide RNA were designed to flank Exon 4 of
zebrafish Glis3. Cas9 will target each gRNA and cleave two base pairs following the Exon 4-4
gRNA PAM site and two base pairs before the Exon 4-2 gRNA PAM site. Cleavage will result in
the removal of three base pairs
, resulting in non-functional zebrafish Glis3. b) DraI digestion was used to linearize DR274
vector. c) In vitro transcription successfully produced Exon 4-2 gRNA.
Exon 4-2 sgRNA Targets Glis3 for Cleavage
To test whether Exon 4-2 sgRNA successfully targets Glis3, Glis3 was PCR amplified
and visualized on an agarose gel after being targeted by Exon 4-2 sgRNA. In the presence of the
Exon 4-2 sgRNA and Cas9, Glis3 was properly cleaved (1.7 kb). To guarantee the cleavage was
not random, Glis3 was visualized in the presence of Cas9 and the absences of sgRNA. The lack
of cleavage showed that Exon 4-2 sgRNA is necessary for Cas9 to target Glis3 (Figure 6). This
was also compared to Glis3 digested with BglII, ensuring that Glis3 can be digested.
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Figure 6: Zebrafish Glis3 was PCR amplified and gel visualized. The presence of a 1.7 kb band
indicates that 150 nM Exon 4-2 gRNA successfully targets Glis3 for cleavage by Cas9. This
sample was compared to uncut Glis3 and Glis3 digested with BglII (positive control).
Optimization of Exon 4-2 Glis3 Targeting
In the presence of a genomic DNA detection enzyme, we tested which concentration of
Exon 4-2 sgRNA would most successfully target Glis3: 150 ng, 300 ng, or 600 ng. After
cleavage, the Glis3 gDNA that was targeted by Exon 4-2 sgRNA (1.7 kb) was visualized through
agarose gel electrophoresis (Figure 7). The sgRNA-targeted Glis3 was compared to Glis3 gDNA
(2.1 kb) and Glis3 DNA digested with SpeI (1.4 kb) to ensure proper cleavage. Gel visualization
showed Exon 4-2 sgRNA successfully targeted Glis3 for cleavage under all concentration
conditions, but 600 ng Exon 4-2 sgRNA was the most efficient (Figure 7).
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Figure 7: To optimize the
CRISPR/Cas9 procedure, Glis3
was targeted with three
concentrations of Exon 4-2 gRNA:
150 nM, 300 nM, and 600 nM.
Each concentration of Exon 4-2
gRNA accurately targeted Glis3
for cleavage, resulting in a 1.7 kb
fragment. 600 nM gRNA was the
most effective concentration.
These measurements were
compared to uncut Glis3 and SpeI
digested Glis3 (positive control).

Exon 4-2 and Exon 4-4 sgRNA Guides Cas9 to Glis3 for Cleavage, not Exon 4-3 sgRNA
In addition to Exon 4-2 sgRNA, Exon 4-3 and Exon 4-4 sgRNA constructs were designed
so any pair could target Exon 4 of Glis3 in zebrafish and cause a frameshift mutation (Figure 5a).
To test the efficacy of each sgRNA, we performed in vitro digestion on Glis3 using each sgRNA
for targeting. Both Exon 4-2 sgRNA and Exon 4-4 sgRNA targeted Glis3 for Cas9 cleavage, but
Exon 4-3 sgRNA did not (Figure 8). As a result, Exon 4-2 and Exon 4-4 sgRNA were used in
combination with Cas9 to target Glis3 and create a frameshift mutation in vivo.
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Figure 8: To test the efficacy of each
gRNA construct we designed—Exon 4-2,
Exon 4-3, and Exon 4-4—a 2.1 kb
fragment of Glis3 was digested with Cas9
in the presence of the gRNA. Exon 4-2
and Exon 4-4 gRNA successfully targeted
Glis3 for Cas9 digestion, however Exon
4-3 gRNA did not.
CRISPR/Cas9 was Microinjected into Zebrafish Embryos
We used a PicoSpritzer III pneumatic microinjector to inject CRISPR/Cas9 constructs
into zebrafish embryos at the single-cell stage (up to 30 minutes after fertilization).
Genotyping of CRISPR/Cas9 Zebrafish
We are currently genotyping our Exon4-2/4-4 zebrafish using Sanger sequencing.
DISCUSSION
Previous studies have shown that Glis3 is involved in the regulation of insulin and
development of type 2 diabetes, however the mechanisms of Glis3-driven insulin regulation have
remained uncharacterized. To better examine the involvement of Glis3 in insulin regulation, we
used CRISPR-Cas9 to knock down Glis3 expression in rat β cells. This experiment allowed us to
measure the impacts of Glis3 down-regulation and its effect on insulin transcription regulation.
Our studies showed that downregulation of Glis3 resulted in subsequent downregulation of Ins2,
decreasing the expression of insulin in rat β cells (Figure 4c). However, knocking down Glis3
did not appear to affect the expression of other transcription factors involved in insulin
18

expression. These results suggest that the Exon3A-Exon3B CRISPR could have been a lowefficacy knockdown or Glis3 does not regulate other genes involved in insulin transcription.
Nonetheless, the resulting downregulation of Ins2 by Glis3 knockdown supports previous studies
showing that Glis3 is necessary for insulin regulation.
One potential shortcoming of CRISPR/Cas9 is the tendency for off-target effects. Offtarget effects occur when the gRNA does not properly target a gene of interest for cleavage
because the gRNA lacks specificity. As a result, the gRNA may target a homologous portion of
DNA to which it is also compatible, cleaving an unintended site (Alkan et. al. 2018). To avoid
off-target effects, we analyzed the efficacy of our gRNAs using Alt-R CRISPR HDR Design
Tool by Integrated DNA Technologies. We then designed our gRNA taking the efficacy of each
gRNA and the probability for off-site targeting into consideration. However, potential off-site
targeting could have resulted in the lower efficacy of our Exon3A-3B CRISPR knockdown. To
further reduce the risk of off-site targeting, we could use whole genome sequencing or
sequencing of high probability off-site targets. Both sequencing methods would indicate whether
mutations occurred outside of our intended locus because of off-site targeting (Martin et. al.
2016). If mutations are not present outside of the locus, it is unlikely off-site targeting occurred.
Following the in vitro studies, we created a Glis3 knockout using CRISPR-Cas9. The
Exon 4-2/Exon4-4 CRISPR was injected into zebrafish to examine the effects of Glis3 in
organismal insulin regulation and pancreas development. We designed multiple guide RNA
constructs targeting different portions of Glis3 Exon 4. Ideally, any combination of two Exon 4
gRNA (Exon 4-2, Exon 4-3, or Exon 4-4) would target different portions of Exon 4, resulting in
cleavage by Cas9 and a frameshift mutation. To create a frameshift mutation that would have
been visible by agarose gel electrophoresis, we planned to target Glis3 using Exon 4-3 and Exon
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4-4 sgRNA, excising 281 base pairs. However, Exon 4-3 did not properly target Exon 4 for
cleavage, so Glis3 was not affected. As a result, we targeted Glis3 with Exon 4-2 and Exon 4-4
sgRNA, cleaving 2-3 base pairs. To remove a larger portion of Glis3 Exon 4, we designed Exon
4-5 gRNA. Pairing Exon 4-5 gRNA with Exon 4-4 gRNA, Cas9 will cleave 409 base pairs,
making it easier to genotype through gel electrophoresis.
Because the excision of three base pairs cannot be easily seen on an agarose gel, we are
currently genotyping the Exon 4-2/4-4 CRISPR zebrafish using Sanger sequencing. When
compared to wild type jh2 zebrafish, sequencing should confirm the presence or absence of our
Glis3 knockout. If the Exon 4-2/4-4 CRISPR successfully and ubiquitously knocks out Glis3 in
our zebrafish, we would outbreed them with jh2 wild type zebrafish to determine germline
transmission and generate a line of heterozygous offspring. The heterozygous line can then be
bred to create homozygous lines used to analyze the impact of Glis3 on structural development
of the zebrafish, β cell dysfunction, and insulin regulation.
However, if the Exon 4-2/4-4 CRISPR does not successfully knock out Glis3, then the
microinjection process could be repeated using Exon 4-5 gRNA in combination with Exon 4-4 or
Exon 4-2 gRNA for a larger, possibly more efficient, Glis3 knockout. A conditional knockout
could also be generated to knock out Glis3 in the tissues in which it is expressed. To create a
conditional knockout of Glis3, Cre-recombinase could be used to target Glis3 in the pancreas (Le
and Sauer 2001). Cre-recombinase would then create a double stranded break that would later be
corrected by non-homologous end joining or homology directed repair, ultimately resulting in
non-functional Glis3 in the pancreas. Whether CRISPR-Cas9 or a conditional knockout method
is used, generating Glis3 knockout zebrafish will be integral to better understanding the role of
Glis3 in pancreatic development, β cell dysfunction, and type 2 diabetes.
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